← Leaderboards
Clive Steven Zent
University Of Rochester
$392,374
Attributed
$392,374
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $216K · FY2022–23$250K$187.5K$125K$62.5K$0
'22
'23
Funding mix
By agency
NIH$392,374 · 1
By mechanism
R21$392,374 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Edward M Schwarz$23,644,757
- Ignacio E. Sanz$71,521,451
- Wojciech Zareba$21,736,071
- David C Linehan$5,269,651
- Arthur J. Moss$13,356,209
Others in their field
Other Rising Stars on “Cytotoxicity”
- Julian A Symons · Hackensack University Medical Center$4,228,031
- Ujjini Havaldar Manjunatha · University Of Texas Med Br Galveston$4,091,689
- James M Balkovec · Hackensack University Medical Center$4,033,569
- Steven Bradfute · Albert Einstein College Of Medicine$3,407,726
- Farshad Tehrani · Actiox Llc$3,301,618
- Debra Burnin · Sri International$3,154,745
Research focus
CytotoxicityAgammaglobulinaemia Tyrosine KinaseAnti-Cd20CytotoxicAttenuatedAntibody-Dependent Cellular PhagocytosisB-Cell Antigen ReceptorBcl2 GeneCurative TreatmentsBlood SpecimenB-LymphocytesB Lymphoid MalignancyCell CountCell MembraneCellsCell SurvivalChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia CellAntigen-Antibody ComplexAntibody-Dependent Cell CytotoxicityClinical TrialsCorrelative StudyCostDesign
Grant awards (2)
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity$176,389
R21 · FY2023 · CA · contact PI
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity$215,985
R21 · FY2022 · CA · contact PI